{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:10:58Z","timestamp":1792300258608,"version":"4.4.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,7,17]],"date-time":"2014-07-17T00:00:00Z","timestamp":1405555200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s10741-014-9452-9","type":"journal-article","created":{"date-parts":[[2014,7,16]],"date-time":"2014-07-16T05:59:20Z","timestamp":1405490360000},"page":"179-191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment"],"prefix":"10.1007","volume":"20","author":[{"given":"Brendan N.","family":"Putko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Shanks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haran","family":"Yogasundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consolato","family":"Sergi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin Y.","family":"Oudit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,17]]},"reference":[{"key":"9452_CR1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-146-6-200703200-00007","volume":"146","author":"JT Clarke","year":"2007","unstructured":"Clarke JT (2007) Narrative review: Fabry disease. Ann Intern Med 146:425\u2013433","journal-title":"Ann Intern Med"},{"key":"9452_CR2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A\u2013replacement therapy in Fabry\u2019s disease. N Engl J Med 345:9\u201316","journal-title":"N Engl J Med"},{"key":"9452_CR3","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJMcps1209279","volume":"368","author":"DA Rao","year":"2013","unstructured":"Rao DA, Lakdawala NK, Miller AL, Loscalzo J (2013) Clinical problem-solving. In the thick of it. N Engl J Med 368:1732\u20131738","journal-title":"N Engl J Med"},{"key":"9452_CR4","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/j.jacc.2013.08.1644","volume":"62","author":"E Arbustini","year":"2013","unstructured":"Arbustini E, Narula N, Dec GW, Reddy KS, Greenberg B, Kushwaha S et al (2013) The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the world heart federation. J Am Coll Cardiol 62:2046\u20132072","journal-title":"J Am Coll Cardiol"},{"key":"9452_CR5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/AJP.0b013e318074c986","volume":"23","author":"B Hoffmann","year":"2007","unstructured":"Hoffmann B, Beck M, Sunder-Plassmann G, Borsini W, Ricci R, Mehta A (2007) Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy\u2014a retrospective analysis from the Fabry outcome survey. Clin J Pain 23:535\u2013542","journal-title":"Clin J Pain"},{"key":"9452_CR6","unstructured":"Keshav S (2006) Gastrointestinal manifestations of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry disease: perspectives from 5 years of FOS, chap 28. Oxford PharmaGenesis, Oxford"},{"key":"9452_CR7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2133.2007.08002.x","volume":"157","author":"CH Orteu","year":"2007","unstructured":"Orteu CH, Jansen T, Lidove O, Jaussaud R, Hughes DA, Pintos-Morell G et al (2007) Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol 157:331\u2013337","journal-title":"Br J Dermatol"},{"key":"9452_CR8","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.survophthal.2008.04.005","volume":"53","author":"N Samiy","year":"2008","unstructured":"Samiy N (2008) Ocular features of Fabry disease: diagnosis of a treatable life-threatening disorder. Surv Ophthalmol 53:416\u2013423","journal-title":"Surv Ophthalmol"},{"key":"9452_CR9","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","volume":"46","author":"A Mehta","year":"2009","unstructured":"Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M et al (2009) Natural course of Fabry disease: changing pattern of causes of death in FOS\u2014Fabry outcome survey. J Med Genet 46:548\u2013552","journal-title":"J Med Genet"},{"key":"9452_CR10","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/ndt\/gfp105","volume":"24","author":"B Oqvist","year":"2009","unstructured":"Oqvist B, Brenner BM, Oliveira JP, Ortiz A, Schaefer R, Svarstad E et al (2009) Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations. Nephrol Dial Transpl 24:1736\u20131743","journal-title":"Nephrol Dial Transpl"},{"key":"9452_CR11","first-page":"227","volume":"48","author":"P Ashton-Prolla","year":"2000","unstructured":"Ashton-Prolla P, Tong B, Shabbeer J, Astrin KH, Eng CM, Desnick RJ (2000) Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype\/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. J Investig Med 48:227\u2013235","journal-title":"J Investig Med"},{"key":"9452_CR12","doi-asserted-by":"crossref","unstructured":"Germain DP (2001) A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant. Contrib Nephrol\u00a0(136): 234\u2013240","DOI":"10.1159\/000060194"},{"issue":"Suppl 2","key":"9452_CR13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1023\/A:1012475908718","volume":"24","author":"JP Grunfeld","year":"2001","unstructured":"Grunfeld JP, Lidove O, Joly D, Barbey F (2001) Renal disease in Fabry patients. J Inherit Metab Dis 24(Suppl 2):71\u201374","journal-title":"J Inherit Metab Dis"},{"issue":"Suppl 2","key":"9452_CR14","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1097\/01.ASN.0000016683.73778.78","volume":"13","author":"M Branton","year":"2002","unstructured":"Branton M, Schiffmann R, Kopp JB (2002) Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol 13(Suppl 2):S139\u2013S143","journal-title":"J Am Soc Nephrol"},{"key":"9452_CR15","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1067\/mhj.2000.105105","volume":"139","author":"A Linhart","year":"2000","unstructured":"Linhart A, Palecek T, Bultas J, Ferguson JJ, Hrudova J, Karetova D et al (2000) New insights in cardiac structural changes in patients with Fabry\u2019s disease. Am Heart J 139:1101\u20131108","journal-title":"Am Heart J"},{"issue":"Suppl 2","key":"9452_CR16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1023\/A:1012428009627","volume":"24","author":"A Linhart","year":"2001","unstructured":"Linhart A, Lubanda JC, Palecek T, Bultas J, Karetova D, Ledvinova J et al (2001) Cardiac manifestations in Fabry disease. J Inherit Metab Dis 24(Suppl 2):75\u201383","journal-title":"J Inherit Metab Dis"},{"key":"9452_CR17","doi-asserted-by":"crossref","first-page":"6014","DOI":"10.2174\/13816128113199990387","volume":"19","author":"A Tuttolomondo","year":"2013","unstructured":"Tuttolomondo A, Pecoraro R, Simonetta I, Miceli S, Arnao V, Licata G et al (2013) Neurological complications of Anderson-Fabry disease. Curr Pharm Des 19:6014\u20136030","journal-title":"Curr Pharm Des"},{"key":"9452_CR18","first-page":"369","volume":"129","author":"M Elleder","year":"1990","unstructured":"Elleder M, Dorazilova V, Bradova V, Belohlavek M, Kral V, Choura M et al (1990) Fabry\u2019s disease with isolated disease of the cardiac muscle, manifesting as hypertrophic cardiomyopathy. Cas Lek Cesk 129:369\u2013372","journal-title":"Cas Lek Cesk"},{"key":"9452_CR19","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJM199102073240607","volume":"324","author":"W Scheidt von","year":"1991","unstructured":"von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG et al (1991) An atypical variant of Fabry\u2019s disease with manifestations confined to the myocardium. N Engl J Med 324:395\u2013399","journal-title":"N Engl J Med"},{"key":"9452_CR20","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","volume":"333","author":"S Nakao","year":"1995","unstructured":"Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M et al (1995) An atypical variant of Fabry\u2019s disease in men with left ventricular hypertrophy. N Engl J Med 333:288\u2013293","journal-title":"N Engl J Med"},{"key":"9452_CR21","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","volume":"28","author":"A Linhart","year":"2007","unstructured":"Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A et al (2007) Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 28:1228\u20131235","journal-title":"Eur Heart J"},{"key":"9452_CR22","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2215\/CJN.05570809","volume":"5","author":"R Mignani","year":"2010","unstructured":"Mignani R, Feriozzi S, Schaefer RM, Breunig F, Oliveira JP, Ruggenenti P et al (2010) Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy. Clin J Am Soc Nephrol 5:379\u2013385","journal-title":"Clin J Am Soc Nephrol"},{"key":"9452_CR23","first-page":"2742","volume-title":"The metabolic and molecular bases of inherited disease","author":"CR Scriver","year":"1995","unstructured":"Scriver CR (1995) The metabolic and molecular bases of inherited disease, vol II. McGraw-Hill, New York, p 2742"},{"key":"9452_CR24","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/jhg.2013.48","volume":"58","author":"T Inoue","year":"2013","unstructured":"Inoue T, Hattori K, Ihara K, Ishii A, Nakamura K, Hirose S (2013) Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study. J Hum Genet 58:548\u2013552","journal-title":"J Hum Genet"},{"key":"9452_CR25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0140-6736(11)61266-X","volume":"379","author":"TP Mechtler","year":"2012","unstructured":"Mechtler TP, Stary S, Metz TF, De Jesus VR, Greber-Platzer S, Pollak A et al (2012) Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet 379:335\u2013341","journal-title":"Lancet"},{"key":"9452_CR26","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","volume":"2","author":"HY Lin","year":"2009","unstructured":"Lin HY, Chong KW, Hsu JH, Yu HC, Shih CC, Huang CH et al (2009) High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet 2:450\u2013456","journal-title":"Circ Cardiovasc Genet"},{"key":"9452_CR27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H et al (2006) High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79:31\u201340","journal-title":"Am J Hum Genet"},{"key":"9452_CR28","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ymgme.2011.05.008","volume":"104","author":"U Feldt-Rasmussen","year":"2011","unstructured":"Feldt-Rasmussen U, Dobrovolny R, Nazarenko I, Ballegaard M, Hasholt L, Rasmussen AK et al (2011) Diagnostic dilemma: a young woman with Fabry disease symptoms, no family history, and a \u201csequencing cryptic\u201d alpha-galactosidase a large deletion. Mol Genet Metab 104:314\u2013318","journal-title":"Mol Genet Metab"},{"key":"9452_CR29","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","volume":"105","author":"B Sachdev","year":"2002","unstructured":"Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ et al (2002) Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105:1407\u20131411","journal-title":"Circulation"},{"key":"9452_CR30","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.CIR.0000139847.74101.03","volume":"110","author":"C Chimenti","year":"2004","unstructured":"Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA et al (2004) Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 110:1047\u20131053","journal-title":"Circulation"},{"key":"9452_CR31","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1136\/heartjnl-2011-300364","volume":"97","author":"P Elliott","year":"2011","unstructured":"Elliott P, Baker R, Pasquale F, Quarta G, Ebrahim H, Mehta AB et al (2011) Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry disease survey. Heart 97:1957\u20131960","journal-title":"Heart"},{"key":"9452_CR32","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/eurjhf\/hfq073","volume":"12","author":"O Havndrup","year":"2010","unstructured":"Havndrup O, Christiansen M, Stoevring B, Jensen M, Hoffman-Bang J, Andersen PS et al (2010) Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women. Eur J Heart Fail 12:535\u2013540","journal-title":"Eur J Heart Fail"},{"key":"9452_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","volume":"51","author":"L Tol van der","year":"2014","unstructured":"van der Tol L, Smid BE, Poorthuis BJ, Biegstraaten M, Deprez RH, Linthorst GE et al (2014) A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet 51:1\u20139","journal-title":"J Med Genet"},{"key":"9452_CR34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1399-0004.1982.tb02080.x","volume":"21","author":"G Bach","year":"1982","unstructured":"Bach G, Rosenmann E, Karni A, Cohen T (1982) Pseudodeficiency of alpha-galactosidase A. Clin Genet 21:59\u201364","journal-title":"Clin Genet"},{"key":"9452_CR35","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/humu.10275","volume":"22","author":"M Yasuda","year":"2003","unstructured":"Yasuda M, Shabbeer J, Benson SD, Maire I, Burnett RM, Desnick RJ (2003) Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele. Hum Mutat 22:486\u2013492","journal-title":"Hum Mutat"},{"key":"9452_CR36","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","volume":"7","author":"M Niemann","year":"2014","unstructured":"Niemann M, Rolfs A, Stork S, Bijnens B, Breunig F, Beer M et al (2014) Gene mutations versus clinically relevant phenotypes-Lyso-Gb3 defines fabry disease. Circ Cardiovasc Genet 7:8\u201316","journal-title":"Circ Cardiovasc Genet"},{"key":"9452_CR37","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38:769\u2013775","journal-title":"J Med Genet"},{"key":"9452_CR38","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","volume":"93","author":"WR Wilcox","year":"2008","unstructured":"Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U et al (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93:112\u2013128","journal-title":"Mol Genet Metab"},{"key":"9452_CR39","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10897-013-9613-3","volume":"22","author":"DA Laney","year":"2013","unstructured":"Laney DA, Bennett RL, Clarke V, Fox A, Hopkin RJ, Johnson J et al (2013) Fabry disease practice guidelines: recommendations of the national society of genetic counselors. J Genet Couns 22:555\u2013564","journal-title":"J Genet Couns"},{"key":"9452_CR40","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","volume":"9","author":"RY Wang","year":"2007","unstructured":"Wang RY, Lelis A, Mirocha J, Wilcox WR (2007) Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 9:34\u201345","journal-title":"Genet Med"},{"key":"9452_CR41","author":"P Juan","year":"2014","unstructured":"Juan P, Hernan A, Beatriz SA, Gustavo C, Antonio M, Eduardo T et al (2014) Fabry Disease: multidisciplinary evaluation after 10 years of treatment with agalsidase beta. JIMD Rep. doi: 10.1007\/8904_2014_310","journal-title":"JIMD Rep"},{"key":"9452_CR42","author":"LJ Anderson","year":"2014","unstructured":"Anderson LJ, Wyatt KM, Henley W, Nikolaou V, Waldek S, Hughes DA et al (2014) Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study. J Inherit Metab Dis. doi: 10.1007\/s10545-014-9717-4","journal-title":"J Inherit Metab Dis"},{"key":"9452_CR43","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/pd.1767","volume":"27","author":"RJ Desnick","year":"2007","unstructured":"Desnick RJ (2007) Prenatal diagnosis of Fabry disease. Prenat Diagn 27:693\u2013694","journal-title":"Prenat Diagn"},{"key":"9452_CR44","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","volume":"342","author":"GM Felker","year":"2000","unstructured":"Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL et al (2000) Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342:1077\u20131084","journal-title":"N Engl J Med"},{"key":"9452_CR45","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","volume":"119","author":"F Weidemann","year":"2009","unstructured":"Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Stork S et al (2009) Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119:524\u2013529","journal-title":"Circulation"},{"key":"9452_CR46","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/FPC.0b013e32830500f4","volume":"18","author":"SH Shin","year":"2008","unstructured":"Shin SH, Kluepfel-Stahl S, Cooney AM, Kaneski CR, Quirk JM, Schiffmann R et al (2008) Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone. Pharmacogenet Genomics 18:773\u2013780","journal-title":"Pharmacogenet Genomics"},{"key":"9452_CR47","unstructured":"Linhart A (2006) The heart in Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry disease: perspectives from 5 years of FOS, chap 20. Oxford PharmaGenesis, Oxford"},{"key":"9452_CR48","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/eurheartj\/ehp588","volume":"31","author":"JC Wu","year":"2010","unstructured":"Wu JC, Ho CY, Skali H, Abichandani R, Wilcox WR, Banikazemi M et al (2010) Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. Eur Heart J 31:1088\u20131097","journal-title":"Eur Heart J"},{"key":"9452_CR49","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.hlc.2007.03.007","volume":"16","author":"N Sadick","year":"2007","unstructured":"Sadick N, Thomas L (2007) Cardiovascular manifestations in Fabry disease: a clinical and echocardiographic study. Heart Lung Circ 16:200\u2013206","journal-title":"Heart Lung Circ"},{"key":"9452_CR50","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.echo.2013.09.005","volume":"26","author":"M Shanks","year":"2013","unstructured":"Shanks M, Thompson RB, Paterson ID, Putko B, Khan A, Chan A et al (2013) Systolic and diastolic function assessment in fabry disease patients using speckle-tracking imaging and comparison with conventional echocardiographic measurements. J Am Soc Echocardiogr 26:1407\u20131414","journal-title":"J Am Soc Echocardiogr"},{"key":"9452_CR51","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","volume":"4","author":"M Niemann","year":"2011","unstructured":"Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M et al (2011) Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging 4:592\u2013601","journal-title":"JACC Cardiovasc Imaging"},{"key":"9452_CR52","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1161\/CIRCIMAGING.113.000482","volume":"6","author":"RB Thompson","year":"2013","unstructured":"Thompson RB, Chow K, Khan A, Chan A, Shanks M, Paterson I et al (2013) T1 mapping with cardiovascular MRI is highly sensitive for fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging 6:637\u2013645","journal-title":"Circ Cardiovasc Imaging"},{"key":"9452_CR53","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","volume":"40","author":"C Kampmann","year":"2002","unstructured":"Kampmann C, Baehner F, Whybra C, Martin C, Wiethoff CM, Ries M et al (2002) Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 40:1668\u20131674","journal-title":"J Am Coll Cardiol"},{"key":"9452_CR54","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.amjcard.2010.07.016","volume":"106","author":"FI Gambarin","year":"2010","unstructured":"Gambarin FI, Disabella E, Narula J, Diegoli M, Grasso M, Serio A et al (2010) When should cardiologists suspect Anderson-Fabry disease? Am J Cardiol 106:1492\u20131499","journal-title":"Am J Cardiol"},{"key":"9452_CR55","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jacc.2011.03.020","volume":"58","author":"M Calcagnino","year":"2011","unstructured":"Calcagnino M, O\u2019Mahony C, Coats C, Cardona M, Garcia A, Janagarajan K et al (2011) Exercise-induced left ventricular outflow tract obstruction in symptomatic patients with Anderson-Fabry disease. J Am Coll Cardiol 58:88\u201389","journal-title":"J Am Coll Cardiol"},{"key":"9452_CR56","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jama.2012.39","volume":"307","author":"KM Flegal","year":"2012","unstructured":"Flegal KM, Carroll MD, Kit BK, Ogden CL (2012) Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999\u20132010. JAMA 307:491\u2013497","journal-title":"JAMA"},{"key":"9452_CR57","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jama.2012.40","volume":"307","author":"CL Ogden","year":"2012","unstructured":"Ogden CL, Carroll MD, Kit BK, Flegal KM (2012) Prevalence of obesity and trends in body mass index among US children and adolescents, 1999\u20132010. JAMA 307:483\u2013490","journal-title":"JAMA"},{"key":"9452_CR58","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jama.2013.184182","volume":"310","author":"CK Chow","year":"2013","unstructured":"Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A et al (2013) Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 310:959\u2013968","journal-title":"JAMA"},{"key":"9452_CR59","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10545-005-0563-2","volume":"28","author":"RJ Kalliokoski","year":"2005","unstructured":"Kalliokoski RJ, Kalliokoski KK, Sundell J, Engblom E, Penttinen M, Kantola I et al (2005) Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease. J Inherit Metab Dis 28:563\u2013573","journal-title":"J Inherit Metab Dis"},{"key":"9452_CR60","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/hrt.2004.054015","volume":"92","author":"PM Elliott","year":"2006","unstructured":"Elliott PM, Kindler H, Shah JS, Sachdev B, Rimoldi OE, Thaman R et al (2006) Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 92:357\u2013360","journal-title":"Heart"},{"key":"9452_CR61","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.ATV.0000209649.60409.38","volume":"26","author":"F Barbey","year":"2006","unstructured":"Barbey F, Brakch N, Linhart A, Rosenblatt-Velin N, Jeanrenaud X, Qanadli S et al (2006) Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler Thromb Vasc Biol 26:839\u2013844","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"9452_CR62","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R et al (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 105:2812\u20132817","journal-title":"Proc Natl Acad Sci USA"},{"key":"9452_CR63","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0002-9149(94)90106-6","volume":"74","author":"WT Pochis","year":"1994","unstructured":"Pochis WT, Litzow JT, King BG, Kenny D (1994) Electrophysiologic findings in Fabry\u2019s disease with a short PR interval. Am J Cardiol 74:203\u2013204","journal-title":"Am J Cardiol"},{"key":"9452_CR64","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.amjcard.2005.05.033","volume":"96","author":"JS Shah","year":"2005","unstructured":"Shah JS, Hughes DA, Sachdev B, Tome M, Ward D, Lee P et al (2005) Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 96:842\u2013846","journal-title":"Am J Cardiol"},{"key":"9452_CR65","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000047318","volume":"94","author":"RE Eckart","year":"2000","unstructured":"Eckart RE, Kinney KG, Belnap CM, Le TD (2000) Ventricular fibrillation refractory to automatic internal cardiac defibrillator in Fabry\u2019s disease. Review of cardiovascular manifestations. Cardiology 94:208\u2013212","journal-title":"Cardiology"},{"key":"9452_CR66","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/clc.22047","volume":"35","author":"D Acharya","year":"2012","unstructured":"Acharya D, Robertson P, Kay GN, Jackson L, Warnock DG, Plumb VJ et al (2012) Arrhythmias in Fabry cardiomyopathy. Clin Cardiol 35:738\u2013740","journal-title":"Clin Cardiol"},{"key":"9452_CR67","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1651-2227.2008.00700.x","volume":"97","author":"C Kampmann","year":"2008","unstructured":"Kampmann C, Wiethoff CM, Whybra C, Baehner FA, Mengel E, Beck M (2008) Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatr 97:463\u2013469","journal-title":"Acta Paediatr"},{"key":"9452_CR68","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1161\/01.CIR.0000061952.27445.A0","volume":"107","author":"M Pieroni","year":"2003","unstructured":"Pieroni M, Chimenti C, Ricci R, Sale P, Russo MA, Frustaci A (2003) Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 107:1978\u20131984","journal-title":"Circulation"},{"key":"9452_CR69","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijcard.2008.04.075","volume":"132","author":"R Toro","year":"2009","unstructured":"Toro R, Perez-Isla L, Doxastaquis G, Barba MA, Gallego AR, Pintos G et al (2009) Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy. Int J Cardiol 132:38\u201344","journal-title":"Int J Cardiol"},{"key":"9452_CR70","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","volume":"26","author":"F Weidemann","year":"2005","unstructured":"Weidemann F, Breunig F, Beer M, Sandstede J, Stork S, Voelker W et al (2005) The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 26:1221\u20131227","journal-title":"Eur Heart J"},{"key":"9452_CR71","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","volume":"108","author":"F Weidemann","year":"2003","unstructured":"Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W et al (2003) Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 108:1299\u20131301","journal-title":"Circulation"},{"key":"9452_CR72","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/CIRCIMAGING.111.968859","volume":"5","author":"C Soullier","year":"2012","unstructured":"Soullier C, Obert P, Doucende G, Nottin S, Cade S, Perez-Martin A et al (2012) Exercise response in hypertrophic cardiomyopathy: blunted left ventricular deformational and twisting reserve with altered systolic-diastolic coupling. Circ Cardiovasc Imaging 5:324\u2013332","journal-title":"Circ Cardiovasc Imaging"},{"key":"9452_CR73","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.ehj.2003.09.017","volume":"24","author":"JC Moon","year":"2003","unstructured":"Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ et al (2003) Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 24:2151\u20132155","journal-title":"Eur Heart J"},{"key":"9452_CR74","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijcard.2011.03.023","volume":"160","author":"S Koeppe","year":"2012","unstructured":"Koeppe S, Neubauer H, Breunig F, Weidemann F, Wanner C, Sandstede J et al (2012) MR-based analysis of regional cardiac function in relation to cellular integrity in Fabry disease. Int J Cardiol 160:53\u201358","journal-title":"Int J Cardiol"},{"key":"9452_CR75","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11547-011-0710-9","volume":"117","author":"G Messalli","year":"2012","unstructured":"Messalli G, Imbriaco M, Avitabile G, Russo R, Iodice D, Spinelli L et al (2012) Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy. Radiol Med 117:19\u201328","journal-title":"Radiol Med"},{"key":"9452_CR76","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jacc.2010.11.013","volume":"57","author":"N Mewton","year":"2011","unstructured":"Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA (2011) Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol 57:891\u2013903","journal-title":"J Am Coll Cardiol"},{"key":"9452_CR77","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCIMAGING.112.000070","volume":"6","author":"DM Sado","year":"2013","unstructured":"Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G et al (2013) Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 6:392\u2013398","journal-title":"Circ Cardiovasc Imaging"},{"key":"9452_CR78","doi-asserted-by":"crossref","unstructured":"Desnick RJ, Wasserstein MP, Banikazemi M (2001) Fabry disease (alpha-galactosidase A deficiency): renal involvement and enzyme replacement therapy. Contrib Nephrol\u00a0(136):174\u2013192","DOI":"10.1159\/000060184"},{"key":"9452_CR79","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","volume":"68","author":"CM Eng","year":"2001","unstructured":"Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L et al (2001) A phase 1\/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68:711\u2013722","journal-title":"Am J Hum Genet"},{"key":"9452_CR80","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","volume":"146","author":"M Banikazemi","year":"2007","unstructured":"Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77\u201386","journal-title":"Ann Intern Med"},{"key":"9452_CR81","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","volume":"5","author":"C Wanner","year":"2010","unstructured":"Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, Linthorst GE et al (2010) Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clin J Am Soc Nephrol 5:2220\u20132228","journal-title":"Clin J Am Soc Nephrol"},{"key":"9452_CR82","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/01.ASN.0000124671.61963.1E","volume":"15","author":"P Kotanko","year":"2004","unstructured":"Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtlander T, Auinger M et al (2004) Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 15:1323\u20131329","journal-title":"J Am Soc Nephrol"},{"key":"9452_CR83","unstructured":"University of Alabama at Birmingham. The Fabrazyme and ARBs and ACE Inhibitor Treatment (FAACET) Study. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00446862 . Accessed July 2 2014"},{"key":"9452_CR84","first-page":"67","volume":"34","author":"A Colombi","year":"1967","unstructured":"Colombi A, Kostyal A, Bracher R, Gloor F, Mazzi R, Tholen H (1967) Angiokeratoma corporis diffusum\u2013Fabry\u2019s disease. Helv Med Acta 34:67\u201383","journal-title":"Helv Med Acta"},{"key":"9452_CR85","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38:750\u2013760","journal-title":"J Med Genet"},{"key":"9452_CR86","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s11906-012-0296-1","volume":"14","author":"CC Tyson","year":"2012","unstructured":"Tyson CC, Nwankwo C, Lin PH, Svetkey LP (2012) The dietary approaches to stop hypertension (DASH) eating pattern in special populations. Curr Hypertens Rep 14:388\u2013396","journal-title":"Curr Hypertens Rep"},{"key":"9452_CR87","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","volume":"8","author":"CM Eng","year":"2006","unstructured":"Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ et al (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 8:539\u2013548","journal-title":"Genet Med"},{"key":"9452_CR88","unstructured":"West ML, Casey R, Clarke JT, Iwanochko M, Moore DF, Sirrs S (2012) Canadian Fabry disease treatment guidelines 2012. http:\/\/www.garrod.ca\/wp-content\/uploads\/Canadian-FD-Treatment-Guidelines-2012.pdf . Accessed July 2 2014"},{"key":"9452_CR89","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1161\/CIRCULATIONAHA.108.841494","volume":"119","author":"BL Thurberg","year":"2009","unstructured":"Thurberg BL, Fallon JT, Mitchell R, Aretz T, Gordon RE, O\u2019Callaghan MW (2009) Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation 119:2561\u20132567","journal-title":"Circulation"},{"key":"9452_CR90","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","volume":"97","author":"R Schiffmann","year":"2000","unstructured":"Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, Myers M et al (2000) Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 97:365\u2013370","journal-title":"Proc Natl Acad Sci USA"},{"key":"9452_CR91","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","volume":"374","author":"A Mehta","year":"2009","unstructured":"Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G et al (2009) Enzyme replacement therapy with agalsidase alfa in patients with Fabry\u2019s disease: an analysis of registry data. Lancet 374:1986\u20131996","journal-title":"Lancet"},{"key":"9452_CR92","first-page":"69","volume":"7","author":"M Alfadhel","year":"2011","unstructured":"Alfadhel M, Sirrs S (2011) Enzyme replacement therapy for Fabry disease: some answers but more questions. Ther Clin Risk Manag 7:69\u201382","journal-title":"Ther Clin Risk Manag"},{"key":"9452_CR93","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10545-014-9677-8","volume":"37","author":"SM Rombach","year":"2014","unstructured":"Rombach SM, Smid BE, Linthorst GE, Dijkgraaf MG, Hollak CE (2014) Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. J Inherit Metab Dis 37:341\u2013352","journal-title":"J Inherit Metab Dis"},{"key":"9452_CR94","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.113.002799","volume":"128","author":"M Pieroni","year":"2013","unstructured":"Pieroni M, Camporeale A, Della Bona R, Sabini A, Cosmi D, Magnolfi A et al (2013) Progression of Fabry cardiomyopathy despite enzyme replacement therapy. Circulation 128:1687\u20131688","journal-title":"Circulation"},{"key":"9452_CR95","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","volume":"274","author":"F Weidemann","year":"2013","unstructured":"Weidemann F, Niemann M, Stork S, Breunig F, Beer M, Sommer C et al (2013) Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med 274:331\u2013341","journal-title":"J Intern Med"},{"key":"9452_CR96","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nm0312-330","volume":"18","author":"R Hersher","year":"2012","unstructured":"Hersher R (2012) Small biotechs raring to cash in on the orphan disease market. Nat Med 18:330\u2013331","journal-title":"Nat Med"},{"key":"9452_CR97","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ymgme.2006.11.008","volume":"90","author":"GJ Murray","year":"2007","unstructured":"Murray GJ, Anver MR, Kennedy MA, Quirk JM, Schiffmann R (2007) Cellular and tissue distribution of intravenously administered agalsidase alfa. Mol Genet Metab 90:307\u2013312","journal-title":"Mol Genet Metab"},{"key":"9452_CR98","first-page":"CD006663","volume":"2","author":"RP El Dib","year":"2013","unstructured":"El Dib RP, Nascimento P, Pastores GM (2013) Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev 2:CD006663","journal-title":"Cochrane Database Syst Rev"},{"key":"9452_CR99","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","volume":"111","author":"SM Sirrs","year":"2014","unstructured":"Sirrs SM, Bichet DG, Casey R, Clarke JT, Lemoine K, Doucette S et al (2014) Outcomes of patients treated through the Canadian Fabry disease initiative. Mol Genet Metab 111:499\u2013506","journal-title":"Mol Genet Metab"},{"key":"9452_CR100","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.chembiol.2011.10.012","volume":"18","author":"AI Guce","year":"2011","unstructured":"Guce AI, Clark NE, Rogich JJ, Garman SC (2011) The molecular basis of pharmacological chaperoning in human alpha-galactosidase. Chem Biol 18:1521\u20131526","journal-title":"Chem Biol"},{"key":"9452_CR101","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.braindev.2012.12.002","volume":"35","author":"Y Suzuki","year":"2013","unstructured":"Suzuki Y (2013) Chaperone therapy update: fabry disease, GM1-gangliosidosis and Gaucher disease. Brain Dev 35:515\u2013523","journal-title":"Brain Dev"},{"key":"9452_CR102","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/mt.2011.271","volume":"20","author":"ER Benjamin","year":"2012","unstructured":"Benjamin ER, Khanna R, Schilling A, Flanagan JJ, Pellegrino LJ, Brignol N et al (2012) Co-administration with the pharmacological chaperone AT1001 increases recombinant human alpha-galactosidase A tissue uptake and improves substrate reduction in Fabry mice. Mol Ther 20:717\u2013726","journal-title":"Mol Ther"},{"key":"9452_CR103","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJM200107053450104","volume":"345","author":"A Frustaci","year":"2001","unstructured":"Frustaci A, Chimenti C, Ricci R, Natale L, Russo MA, Pieroni M et al (2001) Improvement in cardiac function in the cardiac variant of Fabry\u2019s disease with galactose-infusion therapy. N Engl J Med 345:25\u201332","journal-title":"N Engl J Med"},{"key":"9452_CR104","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/humu.21530","volume":"32","author":"X Wu","year":"2011","unstructured":"Wu X, Katz E, Della Valle MC, Mascioli K, Flanagan JJ, Castelli JP et al (2011) A pharmacogenetic approach to identify mutant forms of alpha-galactosidase A that respond to a pharmacological chaperone for Fabry disease. Hum Mutat 32:965\u2013977","journal-title":"Hum Mutat"},{"key":"9452_CR105","doi-asserted-by":"crossref","first-page":"28386","DOI":"10.1074\/jbc.M112.351056","volume":"287","author":"A Siekierska","year":"2012","unstructured":"Siekierska A, De Baets G, Reumers J, Gallardo R, Rudyak S, Broersen K et al (2012) Alpha-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants. J Biol Chem 287:28386\u201328397","journal-title":"J Biol Chem"},{"key":"9452_CR106","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jjcc.2010.08.003","volume":"57","author":"CJ Lee","year":"2011","unstructured":"Lee CJ, Fan X, Guo X, Medin JA (2011) Promoter-specific lentivectors for long-term, cardiac-directed therapy of Fabry disease. J Cardiol 57:115\u2013122","journal-title":"J Cardiol"},{"key":"9452_CR107","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2147\/DDDT.S36131","volume":"6","author":"AP Ruiz de Garibay","year":"2012","unstructured":"Ruiz de Garibay AP, Delgado D, Del Pozo-Rodriguez A, Solinis MA, Gascon AR (2012) Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy. Drug Des Devel Ther 6:303\u2013310","journal-title":"Drug Des Devel Ther"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-014-9452-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-014-9452-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-014-9452-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T17:51:25Z","timestamp":1565632285000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-014-9452-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,17]]},"references-count":107,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["9452"],"URL":"https:\/\/doi.org\/10.1007\/s10741-014-9452-9","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,17]]}}}